Insider Buying: Coya Therapeutics, Inc. (NASDAQ:COYA) CEO Purchases 5,000 Shares of Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CEO Arun Swaminathan purchased 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was acquired at an average price of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now owns 5,000 shares of the company’s stock, valued at $36,700. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Coya Therapeutics Trading Down 1.1 %

NASDAQ COYA traded down $0.08 during midday trading on Tuesday, hitting $7.25. The company had a trading volume of 75,269 shares, compared to its average volume of 71,656. The company has a market capitalization of $121.13 million, a PE ratio of -11.28 and a beta of 0.46. The firm has a 50-day moving average price of $7.05 and a 200-day moving average price of $7.02. Coya Therapeutics, Inc. has a twelve month low of $4.75 and a twelve month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. On average, equities analysts anticipate that Coya Therapeutics, Inc. will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. Renaissance Technologies LLC purchased a new stake in Coya Therapeutics in the 2nd quarter worth $101,000. GHP Investment Advisors Inc. purchased a new stake in Coya Therapeutics in the 3rd quarter worth $169,000. Finally, Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics during the second quarter valued at about $61,000. Institutional investors own 39.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on COYA. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday. Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.